TRCT
ALXN

Tower Research Capital (TRC)’s Alexion Pharmaceuticals ALXN Stock Holding History

Tower Research Capital (TRC)’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-9,367
Closed -$1.72M – 6635
2021
Q2 		$1.72M Sell
9,367
-19,194
-67% -$3.29M 0.04% 366
2021
Q1 		$4.37M Buy
28,561
+23,615
+477% +$3.65M 0.07% 244
2020
Q4 		$773K Sell
4,946
-4,716
-49% -$606K 0.02% 669
2020
Q3 		$1.11M Buy
9,662
+2,791
+41% +$301K 0.01% 896
2020
Q2 		$772K Buy
6,871
+5,992
+682% +$636K 0.03% 690
2020
Q1 		$79K Sell
879
-905
-51% -$88.8K ﹤0.01% 1088
2019
Q4 		$193K Sell
1,784
-2,094
-54% -$224K 0.02% 606
2019
Q3 		$380K Buy
3,878
+1,875
+94% +$211K 0.03% 692
2019
Q2 		$263K Sell
2,003
-2,017
-50% -$260K 0.02% 742
2019
Q1 		$543K Buy
4,020
+3,721
+1,244% +$463K 0.03% 553
2018
Q4 		$29K Buy
+299
New +$35.3K ﹤0.01% 1663
2018
Q3 		– Sell
-12,315
Closed -$1.53M – 4449
2018
Q2 		$1.53M Buy
12,315
+11,984
+3,621% +$1.4M 0.09% 219
2018
Q1 		$37K Buy
331
+272
+461% +$32.5K ﹤0.01% 1857
2017
Q4 		$7K Buy
+59
New +$7.18K ﹤0.01% 2775
2017
Q3 		– Sell
-1,793
Closed -$218K – 4286
2017
Q2 		$218K Buy
1,793
+1,761
+5,503% +$205K 0.02% 324
2017
Q1 		$4K Sell
32
-1,397
-98% -$180K ﹤0.01% 2386
2016
Q4 		$175K Buy
+1,429
New +$175K 0.02% 686
2016
Q3 		– Sell
-203
Closed -$24K – 4787
2016
Q2 		$24K Sell
203
-280
-58% -$39.7K ﹤0.01% 2103
2016
Q1 		$67K Buy
483
+343
+245% +$50.4K 0.01% 645
2015
Q4 		$27K Sell
140
-1,060
-88% -$185K ﹤0.01% 998
2015
Q3 		$188K Buy
+1,200
New +$219K 0.02% 302
2015
Q2 		– Sell
-871
Closed -$151K – 5267
2015
Q1 		$151K Buy
+871
New +$158K 0.02% 582
2014
Q4 		– Sell
-1,978
Closed -$328K – 4950
2014
Q3 		$328K Buy
+1,978
New +$325K 0.04% 354
2014
Q2 		– Sell
-325
Closed -$49K – 4845
2014
Q1 		$49K Sell
325
-329
-50% -$52.3K 0.01% 1111
2013
Q4 		$87K Buy
654
+321
+96% +$38.5K 0.01% 945
2013
Q3 		$38K Sell
333
-52
-14% -$5.71K ﹤0.01% 2167
2013
Q2 		$36K Buy
+385
New +$37.1K ﹤0.01% 1196

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Tower Research Capital (TRC)'s ALXN Position: Q3 2021 in Review

Tower Research Capital (TRC) sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 9,367 shares — an estimated $1.72M sold.

Tower Research Capital (TRC) first reported a position in ALXN in Q2 2013 and held it in 27 quarters. The position peaked at $4.37M in Q1 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Tower Research Capital (TRC) reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 9,367 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.72M.
  • Tower Research Capital (TRC) first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
  • Tower Research Capital (TRC)'s Alexion Pharmaceuticals position peaked at $4.37M in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2021, filed 15 Nov 2021.